Photo from wikipedia
Key Points Question Is delayed adjuvant hormone therapy (AHT) associated with reduced survival in patients with hormone receptor–positive breast cancer? Findings In this cohort study of 144 103 US patients with… Click to show full abstract
Key Points Question Is delayed adjuvant hormone therapy (AHT) associated with reduced survival in patients with hormone receptor–positive breast cancer? Findings In this cohort study of 144 103 US patients with hormone receptor–positive/human epidermal growth factor receptor-2–negative early breast cancer who did not undergo chemotherapy between 2004 and 2014, delays in the initiation of AHT more than 150 days were associated with diminished survival compared with patients who initiated therapy before 150 days. Meaning These results suggest that efforts to avoid delayed AHT may improve survival rates for patients with hormone receptor–positive breast cancer.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!